Eribulin in metastatic breast cancer: Real world data

Breast disease Pub Date : 2023-12-05 DOI:10.3233/bd-230031

C. L. Fernández-Laguna, I. Maray, Lola Macia-Rivas, Cristina Álvarez-Asteinza, Sergio Fernández-Lastras, Veronica Velasco Durántez, Mónica Carbajales Álvarez, Ana Lozan-Blázquez

{"title":"Eribulin in metastatic breast cancer: Real world data","authors":"C. L. Fernández-Laguna, I. Maray, Lola Macia-Rivas, Cristina Álvarez-Asteinza, Sergio Fernández-Lastras, Veronica Velasco Durántez, Mónica Carbajales Álvarez, Ana Lozan-Blázquez","doi":"10.3233/bd-230031","DOIUrl":null,"url":null,"abstract":"BACKGROUND: Metastatic breast cancer (MBC) is incurable. Systemic therapy is the standard treatment; however, an optimal sequence of chemotherapy has not been established. OBJECTIVE: Evaluating effectiveness and safety of eribulin in MBC treatment and comparing the results obtained with published literature. METHODS: Observational, descriptive and retrospective study of patients with MBC treated with eribulin from 01/12/2015 to 30/10/2021. Effectiveness was analysed using Kaplan–Meier-survival-curves, for the overall number of patients treated and stratified by treatment line. Safety was measured according to adverse events (AE) based on CTCAE v5.0. Data analysis was performed using R v4.0.1. RESULTS: They were included in this study 53 women who received eribulin (median age 58 years). Comparison of median survival from this study versus published data were: progression-free-survival (PFS) 3 (IC95%: 3–4) versus 3.7 months and overall-survival (OS) 8 (IC95%: 3–4) versus 13.2 months for the overall number of patients. For the 1–3 line treatment group, PFS was 6 (IC95%: 3-NA) and OS was 15 (IC95%: 6-NA). There were 322 AEs, the most frequent being blood disorders 16% (52), general disorders 12% (38), and gastrointestinal disorders 12% (38). CONCLUSIONS: The median PFS was similar to that reported previously, with lower OS. There was a tendency to achieve better results when eribulin was used earlier. Eribulin is a less well-tolerated drug than published literature.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"113 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/bd-230031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

BACKGROUND: Metastatic breast cancer (MBC) is incurable. Systemic therapy is the standard treatment; however, an optimal sequence of chemotherapy has not been established. OBJECTIVE: Evaluating effectiveness and safety of eribulin in MBC treatment and comparing the results obtained with published literature. METHODS: Observational, descriptive and retrospective study of patients with MBC treated with eribulin from 01/12/2015 to 30/10/2021. Effectiveness was analysed using Kaplan–Meier-survival-curves, for the overall number of patients treated and stratified by treatment line. Safety was measured according to adverse events (AE) based on CTCAE v5.0. Data analysis was performed using R v4.0.1. RESULTS: They were included in this study 53 women who received eribulin (median age 58 years). Comparison of median survival from this study versus published data were: progression-free-survival (PFS) 3 (IC95%: 3–4) versus 3.7 months and overall-survival (OS) 8 (IC95%: 3–4) versus 13.2 months for the overall number of patients. For the 1–3 line treatment group, PFS was 6 (IC95%: 3-NA) and OS was 15 (IC95%: 6-NA). There were 322 AEs, the most frequent being blood disorders 16% (52), general disorders 12% (38), and gastrointestinal disorders 12% (38). CONCLUSIONS: The median PFS was similar to that reported previously, with lower OS. There was a tendency to achieve better results when eribulin was used earlier. Eribulin is a less well-tolerated drug than published literature.

查看原文本刊更多论文

转移性乳腺癌中的 Eribulin：真实世界数据

背景:转移性乳腺癌(MBC)是无法治愈的。全身治疗是标准治疗;然而，一个最佳的化疗顺序尚未确定。目的:评价伊瑞布林治疗MBC的有效性和安全性，并与文献资料进行比较。方法:对2015年12月1日至2021年10月30日接受伊瑞布林治疗的MBC患者进行观察性、描述性和回顾性研究。使用kaplan - meier -生存曲线分析治疗总人数的有效性，并按治疗线分层。以CTCAE v5.0为标准，根据不良事件(AE)进行安全性评价。使用R v4.0.1进行数据分析。结果:本研究纳入53名接受伊瑞布林治疗的女性(中位年龄58岁)。该研究与已发表数据的中位生存期比较为:患者总人数的无进展生存期(PFS) 3 (IC95%: 3 - 4) vs 3.7个月，总生存期(OS) 8 (IC95%: 3 - 4) vs 13.2个月。对于1-3线治疗组，PFS为6 (IC95%: 3-NA)， OS为15 (IC95%: 6- na)。共有322例ae，最常见的是血液疾病16%(52例)，一般疾病12%(38例)，胃肠道疾病12%(38例)。结论:中位PFS与之前报道的相似，OS较低。早期使用伊曲布林有取得更好效果的趋势。与已发表的文献相比，艾里布林是一种耐受性较差的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.